To test whether TBC1D23 is required for the trafficking of CPD, we used CRISPR-Cas9 to remove the TBC1D23 gene from both human embryonic kidney (HEK) 293 cells and the rat insulinoma line INS-1 (Fig. 2A and fig. This evidence concerns the gene TBC1D23 and pancreatic insulinoma.